Abstract: The present invention concerns methods for in vitro detection of an infection by Mycobacterium tuberculosis in mammals, and methods for in vitro distinction between mammals infected with Mycobacterium tuberculosis in which the disease is declared (active form) and mammals which are infected but asymptomatic for tuberculosis (latent form), and a method for in vitro distinction between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis. The present invention also pertains to kits for detection and distinction between infected mammals presenting tuberculosis symptoms and infected mammals with no disease development, and a kit for distinguishing between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis.
December 28, 2006
Date of Patent:
November 16, 2010
Institute Pasteur de Lille, Inserm (Institut National de la Sante Et de la Recherche Medicale), Universite Libre de Bruxelles, Universite du Droit Et de la Sante de Lille II
Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
March 7, 2007
October 1, 2009
Institute Pasteur de Lille, Institute National de la Sante de la Recherche Medicale (Inserm)
Abstract: The invention concerns mixed micelles or micro-aggregates for inducing an immune response containing at least a first lipopeptide comprising a CTL epitope and at least a first lipid motif; and a second lipopeptide comprising at least an auxiliary T epitope and at least a lipid motif, whereof the type can be different from the first lipopeptide motif. Said micelles can be used as medicines and vaccines.
December 2, 1998
Date of Patent:
January 13, 2009
Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique, Institute Pasteur de Lille
Hélène Gras-Masse, Marc Bossus, Guy Lippens, Jean-Michel Wieruszeski, André Tartar, Jean-Gérard Guillet, Isabelle Bourgault-Villada